Brokerages Set Evolent Health, Inc. (NYSE:EVH) PT at $17.71

Evolent Health, Inc. (NYSE:EVH - Get Free Report) has earned a consensus rating of "Buy" from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $17.71.

Several research firms have recently weighed in on EVH. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, March 10th. JMP Securities reissued a "market outperform" rating and issued a $12.00 target price on shares of Evolent Health in a research report on Friday, February 14th. Canaccord Genuity Group dropped their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Citigroup reduced their target price on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a report on Friday, January 10th. Finally, Oppenheimer reduced their price objective on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, January 24th.

Insider Transactions at Evolent Health

In other Evolent Health news, CEO Seth Blackley purchased 55,225 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was purchased at an average cost of $9.01 per share, with a total value of $497,577.25. Following the purchase, the chief executive officer now owns 762,217 shares of the company's stock, valued at approximately $6,867,575.17. The trade was a 7.81 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brendan B. Springstubb acquired 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of $8.75 per share, for a total transaction of $43,750.00. Following the transaction, the director now directly owns 11,842 shares in the company, valued at $103,617.50. The trade was a 73.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 74,000 shares of company stock worth $666,315. 1.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Pilgrim Partners Asia Pte Ltd purchased a new stake in Evolent Health in the fourth quarter worth about $26,000. R Squared Ltd purchased a new position in Evolent Health during the fourth quarter valued at approximately $31,000. AlphaQuest LLC increased its holdings in shares of Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares during the period. Parkside Financial Bank & Trust raised its position in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after acquiring an additional 2,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of Evolent Health during the 4th quarter worth $61,000.

Evolent Health Price Performance

EVH traded up $0.43 on Friday, reaching $9.98. The company had a trading volume of 3,140,758 shares, compared to its average volume of 2,268,929. Evolent Health has a 52-week low of $8.35 and a 52-week high of $33.63. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -12.17 and a beta of 1.20. The business has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $14.11.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). The company had revenue of $646.54 million during the quarter, compared to analysts' expectations of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. As a group, sell-side analysts anticipate that Evolent Health will post 0.08 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.